EUCTR2017-000901-19-ES
Active, not recruiting
Phase 1
Evaluation of the clinical and echographic response to Apremilast through clinical evaluation and through a joint-periarticular-nail echographic index in patients with active psoriatic arthritis. - APREMILAST
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)0 sitesAugust 4, 2017
ConditionsPsoriasic arthritisTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
DrugsOtezla
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Psoriasic arthritis
- Sponsor
- Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
- Status
- Active, not recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Adults equal or over 18 years with Psoriatic Arthritis (PAs) according to CASPAR criteria (Classification Criteria for Psoriatic Arthritis) at the time of selection with involvement of hands and / or feet with active clinical disease (more than two inflamed joints)
- •\- To have 2 or more joints with echographic synovitis at the screening visit
- •\- To have 1 or more echographically affected enthesis at the screening visit
- •\- To accept and to sign the informed consent of the study
- •\- Ability to comply with all tests and visits of specified protocol and to have a permanent address.
- •\- Women of childbearing age should have a negative pregnancy test at the baseline visit. Women of childbearing age who participate in the study should use one of the following contraceptive methods throughout the trial and at least up to 28 days after taking the last dose of study medication.
- •Approved contraceptive options are:
- •· Option 1: Any of the following: hormonal contraceptives (eg, birth control pills, injection, implant, transdermal patch, vaginal ring); Intrauterine device (IUD); tubal ligation; Or that your partner has had a vasectomy
- •· Option 2: male or female condom (a latex condom or non\-latex condom BUT NOT made of a natural \[animal, eg polyurethane] membrane) AND one of the following additional barrier methods: a) Diaphragm with spermicide; B) cervical cap with spermicide; Or c) contraceptive sponge with spermicide.
- •Are the trial subjects under 18? no
Exclusion Criteria
- •\- Concomitant treatment with methotrexate or leflunomide or other DMARDs. Patients may not have taken methotrexate during the month prior to screening, leflunomide during the 2 months prior to screening and other DMARDs during the 15 days prior to screening.
- •\- Prior or current use of biological therapy (anti\-TNF)
- •\-Do not meet any of the inclusion requirements.
- •\- Medical contraindications for taking Apremilast
- •\- Pregnancy or breastfeeding
- •\- History of allergy to any component of the study drug
- •\- Active tuberculosis (TB) or history of incomplete treatment for tuberculosis.
- •\- Substance abuse or history of substance abuse within 6 months prior to screening
- •\- Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks prior to screening.
- •\- Malignancy or history of malignancy (except in situ cutaneous carcinomas of the basal or squamous cells treated (ie, cured) and treated cervical intraepithelial neoplasms or in situ carcinoma of the cervix without evidence of recurrence within The last 5 years)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Assessment of clinical and radiological findings for risk evaluation of secondary interstitial lung diseases associated with cancer treatmentsPatients with cancer or suspected cancer who have interstitial lung lesionsJPRN-UMIN000052426Hamamatsu University School of Medicine300
Completed
Phase 4
Evaluation of the safety and the performance of the TRYPTIK2®C-Plate Cervical Plate System on patient treated for cervical degenerative disease or traumaMyelopathy and/or radiculopathy, or traumaNervous System DiseasesISRCTN11908022Spinart SA42
Not yet recruiting
Not Applicable
Evaluation of clinical and radiographic outcomes in immediate placement of dental implant with and without the procedure of leaving a root fragment when removing a tooth in single rooted teeth â?? A Randomized Controlled Trial.CTRI/2020/01/022701Shweta Yadav
Not yet recruiting
Phase 3
A STUDY TO SEE THE EFFECTS OF PLACING A MATERIAL MADE OF PATIENTS OWN BLOOD IN IMPLANT PLACED IMMEDIATELY AFTER REMOVAL OF TOOTHCTRI/2021/04/032917MONAL SONI18
Completed
Not Applicable
The effect of biodegradable bone cement for the augmentation of internally-fixed hip fracture using intramedullary nail in old aged patientsDiseases of the musculo-skeletal system and connective tissueKCT0003515Kangdong Sacred Heart Hospital20